Applied DNA Sciences (APDN) Stock Forecast, Price Target & Predictions
APDN Stock Forecast
Applied DNA Sciences stock forecast is as follows: an average price target of $1.50 (represents a 9.49% upside from APDN’s last price of $1.37) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
APDN Price Target
The average price target for Applied DNA Sciences (APDN) is $1.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $1.50 to $1.50. This represents a potential 9.49% upside from APDN's last price of $1.37.
APDN Analyst Ratings
According to 1 Wall Street analysts, Applied DNA Sciences's rating consensus is 'Buy'. The analyst rating breakdown for APDN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Applied DNA Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 10, 2024 | Yi Chen | H.C. Wainwright | $1.50 | $0.54 | 179.80% | 9.49% |
| Aug 08, 2022 | - | H.C. Wainwright | $8.00 | $5.82 | 37.54% | 483.94% |
| May 16, 2022 | - | H.C. Wainwright | $4.00 | $1.40 | 185.71% | 191.97% |
The latest Applied DNA Sciences stock forecast, released on Jun 10, 2024 by Yi Chen from H.C. Wainwright, set a price target of $1.50, which represents a 179.80% increase from the stock price at the time of the forecast ($0.54), and a 9.49% increase from APDN last price ($1.37).
Applied DNA Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $1.50 |
| Last Closing Price | $1.37 | $1.37 | $1.37 |
| Upside/Downside | -100.00% | -100.00% | 9.49% |
In the current month, the average price target of Applied DNA Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Applied DNA Sciences's last price of $1.37. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Applied DNA Sciences's last stock rating was published by H.C. Wainwright on Jun 10, 2024. The company gave APDN a "Buy" rating, the same as its previous rate.
Applied DNA Sciences Financial Forecast
Applied DNA Sciences Revenue Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $891.16K | $779.74K | $2.92M | $4.41M | $5.26M | $3.56M | $4.30M | $6.15M | $4.17M | $3.04M | $1.70M | $2.67M | $1.62M | $313.99K | $431.52K | $552.47K | $633.52K | $1.67M | $2.05M | $778.47K | $1.04M | $905.37K | $573.32K |
| Avg Forecast | $1.71M | $1.46M | $1.10M | $1.04M | $899.00K | $1.08M | $951.00K | $776.00K | $1.68M | $2.56M | $4.13M | $4.17M | $4.10M | $3.60M | $4.50M | $4.04M | $2.30M | $3.13M | $2.60M | $1.36M | $707.50K | $802.00K | $946.00K | $747.00K | $2.11M | $3.54M | $1.32M | $1.78M | $910.00K | $447.86K |
| High Forecast | $1.90M | $1.62M | $1.22M | $1.15M | $998.89K | $1.20M | $1.06M | $862.22K | $1.87M | $2.84M | $4.58M | $4.63M | $4.56M | $3.60M | $4.50M | $4.04M | $2.30M | $3.13M | $2.60M | $1.36M | $707.50K | $802.00K | $946.00K | $747.00K | $2.11M | $3.54M | $1.32M | $2.14M | $1.09M | $537.43K |
| Low Forecast | $1.52M | $1.30M | $979.11K | $922.22K | $799.11K | $959.11K | $845.33K | $689.78K | $1.49M | $2.27M | $3.67M | $3.71M | $3.65M | $3.60M | $4.50M | $4.04M | $2.30M | $3.13M | $2.60M | $1.36M | $707.50K | $802.00K | $946.00K | $747.00K | $2.11M | $3.54M | $1.32M | $1.43M | $728.00K | $358.28K |
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | - | - | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 20 |
| Surprise % | - | - | - | - | - | - | - | 1.15% | 0.46% | 1.14% | 1.07% | 1.26% | 0.87% | 1.19% | 1.37% | 1.03% | 1.32% | 0.54% | 1.03% | 1.19% | 0.44% | 0.54% | 0.58% | 0.85% | 0.79% | 0.58% | 0.59% | 0.59% | 0.99% | 1.28% |
Applied DNA Sciences's average Quarter revenue forecast for Mar 24 based on 0 analysts is $951.00K, with a low forecast of $845.33K, and a high forecast of $1.06M. APDN's average Quarter revenue forecast represents a 6.71% increase compared to the company's last Quarter revenue of $891.16K (Dec 23).
Applied DNA Sciences EBITDA Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | - | - | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 20 |
| EBITDA | - | - | - | - | - | - | - | $-3.79M | $-3.41M | $-2.86M | $-5.61M | $1.76M | $-8.91M | $-4.27M | $-2.06M | $-4.31M | $-2.51M | $-3.12M | $-2.96M | $-1.10M | $-4.01M | $-3.20M | $-2.86M | $-2.54M | $-1.79M | $-1.34M | $-2.53M | $-1.99M | $-3.26M | $-3.28M |
| Avg Forecast | $-1.63M | $-1.39M | $-1.05M | $-992.14K | $-859.70K | $-1.03M | $-909.42K | $-742.07K | $-1.61M | $-2.45M | $-3.95M | $-3.99M | $-3.93M | $-3.44M | $-1.87M | $-3.86M | $-2.20M | $-2.99M | $-1.32M | $-1.30M | $-676.57K | $-766.94K | $-2.78M | $-714.34K | $-2.02M | $-3.38M | $-2.88M | $-2.55M | $-3.27M | $-2.40M |
| High Forecast | $-1.45M | $-1.24M | $-936.31K | $-881.90K | $-764.17K | $-917.18K | $-808.38K | $-659.62K | $-1.43M | $-2.17M | $-3.51M | $-3.54M | $-3.49M | $-3.44M | $-1.49M | $-3.86M | $-2.20M | $-2.99M | $-1.05M | $-1.30M | $-676.57K | $-766.94K | $-2.23M | $-714.34K | $-2.02M | $-3.38M | $-2.30M | $-2.04M | $-2.61M | $-1.92M |
| Low Forecast | $-1.81M | $-1.55M | $-1.17M | $-1.10M | $-955.22K | $-1.15M | $-1.01M | $-824.53K | $-1.79M | $-2.72M | $-4.38M | $-4.43M | $-4.36M | $-3.44M | $-2.24M | $-3.86M | $-2.20M | $-2.99M | $-1.58M | $-1.30M | $-676.57K | $-766.94K | $-3.34M | $-714.34K | $-2.02M | $-3.38M | $-3.45M | $-3.06M | $-3.92M | $-2.88M |
| Surprise % | - | - | - | - | - | - | - | 5.11% | 2.12% | 1.17% | 1.42% | -0.44% | 2.27% | 1.24% | 1.11% | 1.12% | 1.14% | 1.04% | 2.24% | 0.85% | 5.93% | 4.17% | 1.03% | 3.55% | 0.89% | 0.40% | 0.88% | 0.78% | 1.00% | 1.37% |
0 analysts predict APDN's average Quarter EBITDA for Mar 23 to be $-3.95M, with a high of $-3.51M and a low of $-4.38M. This is -324.44% lower than Applied DNA Sciences's previous annual EBITDA (Dec 22) of $1.76M.
Applied DNA Sciences Net Income Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | - | - | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 20 |
| Net Income | - | - | - | - | - | - | - | $-1.18M | $-3.59M | $-3.10M | $588.34K | $-3.84M | $-773.07K | $-1.12M | $-1.13M | $-4.81M | $-6.20M | $-3.53M | $122.06K | $-8.41M | $-4.12M | $-3.29M | $-2.95M | $-2.71M | $-1.23M | $-1.52M | $-2.74M | $-2.15M | $-3.44M | $-3.49M |
| Avg Forecast | $-903.21K | $-943.35K | $-1.12M | $-1.30M | $-1.36M | $-1.99M | $-18.06M | $-24.89M | $-21.28M | $-19.27M | $-16.06M | $-23.28M | $-18.87M | $-28.50M | $-2.29M | $-21.41M | $-29.97M | $-21.14M | $-1.52M | $-43.35M | $-41.75M | $-54.19M | $-2.88M | $-99.55M | $-101.16M | $-48.17M | $-2.99M | $-2.74M | $-3.43M | $-2.52M |
| High Forecast | $-772.75K | $-807.11K | $-961.66K | $-1.12M | $-1.17M | $-1.70M | $-15.45M | $-21.29M | $-18.20M | $-16.49M | $-13.74M | $-19.92M | $-16.14M | $-28.50M | $-1.83M | $-21.41M | $-29.97M | $-21.14M | $-1.21M | $-43.35M | $-41.75M | $-54.19M | $-2.30M | $-99.55M | $-101.16M | $-48.17M | $-2.39M | $-2.19M | $-2.74M | $-2.02M |
| Low Forecast | $-1.03M | $-1.08M | $-1.29M | $-1.49M | $-1.56M | $-2.27M | $-20.67M | $-28.48M | $-24.35M | $-22.05M | $-18.38M | $-26.65M | $-21.59M | $-28.50M | $-2.75M | $-21.41M | $-29.97M | $-21.14M | $-1.82M | $-43.35M | $-41.75M | $-54.19M | $-3.45M | $-99.55M | $-101.16M | $-48.17M | $-3.58M | $-3.28M | $-4.11M | $-3.03M |
| Surprise % | - | - | - | - | - | - | - | 0.05% | 0.17% | 0.16% | -0.04% | 0.17% | 0.04% | 0.04% | 0.49% | 0.22% | 0.21% | 0.17% | -0.08% | 0.19% | 0.10% | 0.06% | 1.03% | 0.03% | 0.01% | 0.03% | 0.92% | 0.79% | 1.00% | 1.38% |
Applied DNA Sciences's average Quarter net income forecast for Jun 23 is $-19.27M, with a range of $-22.05M to $-16.49M. APDN's average Quarter net income forecast represents a -3375.04% decrease compared to the company's last Quarter net income of $588.34K (Mar 23).
Applied DNA Sciences SG&A Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | - | - | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 20 |
| SG&A | - | - | - | - | - | - | - | $3.08M | $3.31M | $3.29M | $3.52M | $2.63M | $3.87M | $3.01M | $3.41M | $4.66M | $2.31M | $3.24M | $3.56M | $3.50M | $2.89M | $2.59M | $2.29M | $2.37M | $2.26M | $2.41M | $2.53M | $2.00M | $3.23M | $3.12M |
| Avg Forecast | $3.53M | $3.01M | $2.28M | $2.15M | $1.86M | $2.23M | $1.97M | $1.60M | $3.47M | $5.29M | $8.53M | $8.62M | $8.49M | $7.45M | $4.45M | $8.34M | $4.75M | $6.47M | $5.38M | $2.81M | $1.46M | $1.66M | $1.96M | $1.54M | $4.37M | $7.31M | $2.73M | $3.69M | $1.88M | $925.97K |
| High Forecast | $3.92M | $3.35M | $2.53M | $2.38M | $2.07M | $2.48M | $2.18M | $1.78M | $3.86M | $5.88M | $9.48M | $9.58M | $9.43M | $7.45M | $5.34M | $8.34M | $4.75M | $6.47M | $5.38M | $2.81M | $1.46M | $1.66M | $1.96M | $1.54M | $4.37M | $7.31M | $2.73M | $4.42M | $2.26M | $1.11M |
| Low Forecast | $3.14M | $2.68M | $2.02M | $1.91M | $1.65M | $1.98M | $1.75M | $1.43M | $3.09M | $4.70M | $7.58M | $7.66M | $7.54M | $7.45M | $3.56M | $8.34M | $4.75M | $6.47M | $5.38M | $2.81M | $1.46M | $1.66M | $1.96M | $1.54M | $4.37M | $7.31M | $2.73M | $2.95M | $1.51M | $740.77K |
| Surprise % | - | - | - | - | - | - | - | 1.92% | 0.95% | 0.62% | 0.41% | 0.30% | 0.46% | 0.40% | 0.77% | 0.56% | 0.49% | 0.50% | 0.66% | 1.25% | 1.98% | 1.56% | 1.17% | 1.54% | 0.52% | 0.33% | 0.93% | 0.54% | 1.72% | 3.37% |
Applied DNA Sciences's average Quarter SG&A projection for Mar 24 is $1.97M, based on 0 Wall Street analysts, with a range of $1.75M to $2.18M. The forecast indicates a -36.25% fall compared to APDN last annual SG&A of $3.08M (Dec 23).
Applied DNA Sciences EPS Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | - | - | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 9 | 20 |
| EPS | - | - | - | - | - | - | - | $-0.09 | $-0.27 | $-0.24 | $0.05 | $-0.30 | $-0.09 | $-0.13 | $-0.14 | $-0.64 | $-0.83 | $-0.47 | $-0.21 | $-1.54 | $-0.76 | $-0.72 | $-0.79 | $-1.14 | $-0.52 | $-1.60 | $-3.28 | $-2.86 | $-5.22 | $-5.80 |
| Avg Forecast | $-0.23 | $-0.23 | $-0.28 | $-0.33 | $-0.34 | $-0.49 | $-4.50 | $-6.20 | $-5.30 | $-4.80 | $-4.00 | $-5.80 | $-4.70 | $-7.10 | $-6.67 | $-5.33 | $-7.47 | $-5.27 | $-4.27 | $-10.80 | $-10.40 | $-13.50 | $-15.40 | $-24.80 | $-25.20 | $-12.00 | $-48.00 | $-6.12 | $-0.13 | $-0.08 |
| High Forecast | $-0.19 | $-0.20 | $-0.24 | $-0.28 | $-0.29 | $-0.42 | $-3.85 | $-5.30 | $-4.53 | $-4.11 | $-3.42 | $-4.96 | $-4.02 | $-7.10 | $-6.67 | $-5.33 | $-7.47 | $-5.27 | $-4.27 | $-10.80 | $-10.40 | $-13.50 | $-15.40 | $-24.80 | $-25.20 | $-12.00 | $-48.00 | $-4.90 | $-0.10 | $-0.06 |
| Low Forecast | $-0.26 | $-0.27 | $-0.32 | $-0.37 | $-0.39 | $-0.57 | $-5.15 | $-7.10 | $-6.07 | $-5.49 | $-4.58 | $-6.64 | $-5.38 | $-7.10 | $-6.67 | $-5.33 | $-7.47 | $-5.27 | $-4.27 | $-10.80 | $-10.40 | $-13.50 | $-15.40 | $-24.80 | $-25.20 | $-12.00 | $-48.00 | $-7.34 | $-0.16 | $-0.10 |
| Surprise % | - | - | - | - | - | - | - | 0.01% | 0.05% | 0.05% | -0.01% | 0.05% | 0.02% | 0.02% | 0.02% | 0.12% | 0.11% | 0.09% | 0.05% | 0.14% | 0.07% | 0.05% | 0.05% | 0.05% | 0.02% | 0.13% | 0.07% | 0.47% | 40.15% | 72.50% |
According to 0 Wall Street analysts, Applied DNA Sciences's projected average Quarter EPS for Jun 23 is $-4.80, with a low estimate of $-5.49 and a high estimate of $-4.11. This represents a -9700.00% decrease compared to APDN previous annual EPS of $0.05 (Mar 23).
Applied DNA Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DRIO | DarioHealth | $0.95 | $10.75 | 1031.58% | Buy |
| STIM | Neuronetics | $0.73 | $8.00 | 995.89% | Buy |
| OCX | OncoCyte | $3.08 | $8.08 | 162.34% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| XGN | Exagen | $2.96 | $6.00 | 102.70% | Buy |
| BDSX | Biodesix | $1.77 | $3.00 | 69.49% | Buy |
| PSNL | Personalis | $5.69 | $7.75 | 36.20% | Hold |
| APDN | Applied DNA Sciences | $1.37 | $1.50 | 9.49% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
APDN Forecast FAQ
Is Applied DNA Sciences a good buy?
Yes, according to 1 Wall Street analysts, Applied DNA Sciences (APDN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of APDN's total ratings.
What is APDN's price target?
Applied DNA Sciences (APDN) average price target is $1.5 with a range of $1.5 to $1.5, implying a 9.49% from its last price of $1.37. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Applied DNA Sciences stock go up soon?
According to Wall Street analysts' prediction for APDN stock, the company can go up by 9.49% (from the last price of $1.37 to the average price target of $1.5), up by 9.49% based on the highest stock price target, and up by 9.49% based on the lowest stock price target.
Can Applied DNA Sciences stock reach $2?
APDN's average twelve months analyst stock price target of $1.5 does not support the claim that Applied DNA Sciences can reach $2 in the near future.
What are Applied DNA Sciences's analysts' financial forecasts?
Applied DNA Sciences's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $3.7M (high $4.12M, low $3.29M), average EBITDA is $-3.543M (high $-3.149M, low $-3.937M), average net income is $-46.305M (high $-39.616M, low $-52.993M), average SG&A $7.66M (high $8.51M, low $6.81M), and average EPS is $-11.535 (high $-9.869, low $-13.201). APDN's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $5.3M (high $5.89M, low $4.72M), average EBITDA is $-5.073M (high $-4.509M, low $-5.636M), average net income is $-4.275M (high $-3.658M, low $-4.893M), average SG&A $10.97M (high $12.19M, low $9.75M), and average EPS is $-1.065 (high $-0.911, low $-1.219).
Did the APDN's actual financial results beat the analysts' financial forecasts?
Based on Applied DNA Sciences's last annual report (Sep 2023), the company's revenue was $13.37M, beating the average analysts forecast of $12.53M by 6.66%. Apple's EBITDA was $-10.953M, missing the average prediction of $-11.985M by -8.61%. The company's net income was $-9.947M, missing the average estimation of $-79.884M by -87.55%. Apple's SG&A was $12.75M, missing the average forecast of $25.91M by -50.79%. Lastly, the company's EPS was $-0.76, missing the average prediction of $-19.9 by -96.18%. In terms of the last quarterly report (Dec 2023), Applied DNA Sciences's revenue was $891.16K, beating the average analysts' forecast of $776K by 14.84%. The company's EBITDA was $-3.789M, beating the average prediction of $-742K by 410.60%. Applied DNA Sciences's net income was $-1.183M, missing the average estimation of $-24.888M by -95.25%. The company's SG&A was $3.08M, beating the average forecast of $1.6M by 92.24%. Lastly, the company's EPS was $-0.0865, missing the average prediction of $-6.2 by -98.60%